You are here

Chronic Anemia in CML Patients Responsive to Imatinib

This article is a retrospective, single-institution review of the incidence and clinical characteristics of late chronic anemia associated with prolonged use of imatinib for patients with chronic myeloid leukemia. The authors reported a 30% incidence of late chronic anemia associated with a prolonged use of imatinib, with no effect on overall survival.

The authors reported a 30% incidence of late chronic anemia associated with a prolonged use of imatinib, with no effect on overall survival.

Larger studies are needed to further evaluate the association before a more definitive answer can be determined.
– Jarett Feldman, MD

http://www.practiceupdate.com/journalscan/14318